s-warfarin

DRUG2 trials

Sponsors

Biogen, Daiichi Sankyo

Conditions

Relapsing-Remitting Multiple SclerosisSolid Tumors

Phase 1

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

CompletedNCT01517399

Daiichi SankyoSolid Tumors

Start: 2011-12-31End: 2013-09-30Updated: 2019-02-12

Phase 3

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

CompletedNCT01462318

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2011-11-30End: 2016-01-31Updated: 2017-03-14

Related Papers

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Therapeutic Advances in Neurological Disorders2021-01-016 citations

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.

2016-07-1314 citations

Abstract C85: Drug interaction study of tivantinib in cancer subjects using a cocktail approach.

Molecular Cancer Therapeutics2013-11-01